The DOI matches its Crossref record.
The Influence of HLA Class I Alleles and Heterozygosity on the Outcome of Human T Cell Lymphotropic Virus Type I Infection
Abstract
The inflammatory disease human T cell lymphotropic virus type I (HTLV-I)-associated myelopathy (HAM/TSP) occurs in only 1–2% of HTLV-I-infected individuals and is associated with a high provirus load of HTLV-I. We hypothesize that a person’s risk of developing HAM/TSP depends upon the efficiency of their immune response to the virus, which differs between individuals because of polymorphism in genes that influence this response. Previously we showed that the possession of HLA-A*02 was associated with a lower risk of HAM/TSP, and with a lower provirus load in healthy carriers of HTLV-I. However, HLA-A*02 did not account for all the observed difference in the risk of HAM/TSP. Here we present evidence, in the same study population in Japan, that HLA-Cw*08 was also associated with disease protection (probability value, two-tailed test = 0.002) and with a lower proviral load in healthy carriers. Possession of the A*02 and/or Cw*08 genes prevented 36% of potential HAM/TSP cases. In contrast, HLA-B*5401 was associated with a higher susceptibility to HAM/TSP (probability value, two-tailed test = 0.0003) and with a higher provirus load in HAM/TSP patients. At a given provirus load, B*5401 appeared to increase the risk of disease. The fraction of HAM/TSP cases attributable to B*5401 was 17%. Furthermore, individuals who were heterozygous at all three HLA class I loci have a lower HTLV-I provirus load than those who were homozygous at one or more loci. These results are consistent with the proposal that a strong class I-restricted CTL response to HTLV-I reduces the proviral load and hence the risk of disease.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Specific HLA alleles have been reported as determinants of HAM and ATL development and disease severity.
“Specific HLA alleles have been reported as determinants of HAM and ATL development and disease severity [276,277], but allele determinants present in one population may not be reflected in another.”
From Current State of Therapeutics for HTLV-1 (2024) · cites this paper as [276]
Citations
Cites
No references could be resolved yet.
Research works printed but not linked: 67
- 1990, Nature, 245
- 1992, Virology, 628
- 1991, Int. Immunol., 761
- 1986, EMBO J., 2883
- 1997, J. Acquir. Immune Defic. Syndr. Hum. Retrovirol., 70
- 1998, J. Neurovirol., 586
- 1999, J. Acquir. Immune Defic. Syndr., 92
- 1999, Philos. Trans. R. Soc. Lond. B. Biol. Sci., 691
- 1996, Semin. Virol., 41
- 1998, J. Exp. Med., 223
- 1998, J. Immunol., 482
- 1993, Med. Hypotheses, 542
- 1993, J. Exp. Med., 1567
- 1997, J. Immunol., 2018
- 1997, N. Engl. J. Med., 839
- 1994, J. Virol., 2860
- 1996, Virology, 139
- 1999, Proc. Natl. Acad. Sci. USA, 3848
- 1994, J. Virol., 6778
- 2000, Blood, 1386
- 1998, Annu. Rev. Immunol., 593
- 1988, Ann. Neurol., 143
- 1996, J. Acquir. Immune Defic. Syndr. Hum. Retrovirol., S119
- 1991, Tissue Antigens, 230
- 1999, Science, 1748
- 1999, AIDS Res. Hum. Retroviruses, 317
- 1997, Nat Genet, 11
- 1990, Human Retrovirology: HTLV, 191
- 1995, Tissue Antigens, 355
- 1997, Tissue Antigens, 100
- 1997, Tissue Antigens, 297
- 1998, Tissue Antigens, 605
- 1995, Br. Med. J., 170
- 1982, Case-Control Studies
- 1996, Tissue Antigens, 55
- 1997, Immunogenetics, 199
- 1999, Microbiol. Mol. Biol. Rev., 308
- 2000, J. Theor. Biol., 65
- 1977, Eur. J. Immunol., 580
- 1988, Nature, 167
- 1993, J. Virol., 438
- 1991, J. Virol., 4051
- 1997, AIDS, 1884
- 1997, J. Clin. Invest., 752
- 1980, Br. J. Dermatol., 179
- 1998, Hum. Mol. Genet., 1537
- 1999, J. Infect. Dis., 1077
- 1994, Tissue Antigens, 7
- 1994, Tissue Antigens, 166
- 1991, Nature, 453
- 1997, Annu. Rev. Immunol., 271
- 1975, Lancet, 1406
- 1995, J. Virol., 7147
- 1996, Immunol. Today, 261
- 1996, Immunol. Cell Biol., 444
- 1999, J. Infect. Dis., 880
- 2000, Tissue Antigens, 10
- 1999, Tissue Antigens, 194
- 1992, HLA 1991, 1065
- 1999, Hum. Biol., 353
- 1998, Hepatology, 240
- 1998, Eur. J. Gastroenterol. Hepatol., 859
- 1990, Am. Rev. Respir. Dis., 1459
- 1998, Am. J. Respir. Crit. Care Med., 846
- 2000, Am. J. Hum. Genet., 501
- 1999, Tissue Antigens, 178
- 1999, Nature, 921
Cited by
Sorted by citations
Saito, M., Matsuzaki, T., Satou, Y., Yasunaga, J.-I., Saito, K., Arimura, K., Matsuoka, M., & Ohara, Y. (2009) · Retrovirology · doi:10.1186/1742-4690-6-19 · Cited by 184
Current State of Therapeutics for HTLV-1
Wang, T. T., Hirons, A., Doerflinger, M., Morris, K. V., Ledger, S., Purcell, D. F. J., Kelleher, A. D., & Ahlenstiel, C. L. (2024) · Viruses · doi:10.3390/v16101616 · Cited by 22
“The CRISPR/Cas9 editing approach has demonstrated some success in targeting HIV-1 in vitro and in vivo [295,296], the most promising of which is a proof-of-concept study observing effective elimination of proviral DNA in infected mice [297], but this result has yet to be replicated in HTLV-1.”
Background
Metadata
- Authors
- Jeffery, K. J. M., Siddiqui, A. A., Bunce, M., Lloyd, A. L., Vine, A. M., Witkover, A. D., Izumo, S., Usuku, K., Welsh, K. I., Osame, M., & Bangham, C. R. M.
- Affiliations
- Imperial College London (GB)
- Churchill Hospital (GB)
- Institute for Advanced Study (US)
- Division of Molecular Pathology, Centre for Chronic Viral Diseases , Kagoshima ,
- Kagoshima University (JP)
- Venue
- The Journal of Immunology
- Publisher
- Oxford University Press (OUP)
- Published
- 2000-12
- Volume
- 165
- Issue
- 12
- Pages
- 7278-7284
- ISSN
- 0022-1767 (ISSN-L)
- 1550-6606
- OpenAlex
- W2153984726
- Cited by
- 222
- References
- 0
- Citations by year
- 2026: 3 · 2025: 1 · 2024: 5 · 2023: 4 · 2022: 2 · 2021: 6 · 2020: 7 · 2019: 10 · 2018: 1 · 2017: 5 · 2016: 5 · 2015: 5 · 2014: 11 · 2013: 15 · 2012: 13
- FWCI
- 2.72
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Immunology (publishedVersion)
- PubMed (publishedVersion)
- Murdoch University Research Portal (submittedVersion)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and Retrovirus Studies
- Life Sciences › Immunology and Microbiology › Virology › HIV Research and Treatment
- Health Sciences › Medicine › Epidemiology › Hepatitis B Virus Studies
- Keywords
- HTLV-1, HAM/TSP, HLA class I alleles, HLA-A*02, HLA heterozygosity, proviral load, disease susceptibility, cytotoxic T lymphocyte response, genetic polymorphism
- MeSH terms
- Alleles, Female, Genes, MHC Class I, Genetic Carrier Screening, HLA Antigens, Humans, Proviruses, Risk Factors, HLA-B Antigens, HLA-C Antigens, Human T-lymphotropic virus 1, Paraparesis, Tropical Spastic, HLA-A2 Antigen, Linkage Disequilibrium, Disease Progression, Viral Load, Genetic Predisposition to Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review